As oligo manufacturers scale up production from lab-scale to clinical and commercial scales, they may require volumes of hazardous materials that drive additional facility design considerations.
Bill Jarvis
Advertisement
Bill Jarvis is senior fellow, Pharmaceutical Process, at CRB.
Articles by Bill Jarvis
Advertisement
Latest Updated Articles
Oligonucleotide Production FacilitiesNovember 15th 2023
Advertisement
Advertisement